Clinical trial
Bone Effects of Teriparatide Following Alendronate
NCT00191893 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191893 |
|---|---|
| Title | Bone Effects of Teriparatide Following Alendronate |
| Official title | Bone Effects of Subcutaneous Teriparatide Following Discontinuation of Alendronate Treatment in Postmenopausal Women With Osteoporosis |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | teriparatide |
| Enrollment | 66 |
| Start date | Sep 1, 2003 |
| Completion | Nov 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | Austria, Czechia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: